Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunome, Inc. - Common Stock
(NQ:
IMNM
)
11.84
+0.76 (+6.90%)
Streaming Delayed Price
Updated: 12:41 PM EST, Feb 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immunome, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 31, 2025
From
Immunome, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 30, 2025
Via
Benzinga
Immunome Announces Pricing of Upsized Public Offering of Common Stock
January 29, 2025
From
Immunome, Inc.
Via
Business Wire
Curious about the stocks that are showing activity after the closing bell on Wednesday?
January 29, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via
Chartmill
Analyst Expectations For Immunome's Future
November 08, 2024
Via
Benzinga
Immunome Announces Proposed Public Offering of Common Stock
January 29, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025
From
Immunome, Inc.
Via
Business Wire
Hummingbird Bioscience Licenses Novel Antibodies to Immunome
January 07, 2025
From
Hummingbird Bioscience
Via
GlobeNewswire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 02, 2025
From
Immunome, Inc.
Via
Business Wire
3 Small-Cap Stocks With Big Growth Potential
December 13, 2024
Small-cap companies may give investors more targeted exposure to the U.S. economy; these companies are three leaders in the space.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
November 27, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
November 13, 2024
From
Immunome, Inc.
Via
Business Wire
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
November 08, 2024
Via
Benzinga
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
November 05, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
October 29, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
October 18, 2024
From
Immunome, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
October 11, 2024
Via
Benzinga
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
October 08, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 08, 2024
From
Immunome, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
October 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 01, 2024
Via
Benzinga
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
September 13, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Stock Sees RS Rating Jump To 91
August 20, 2024
Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91.
Via
Investor's Business Daily
IMNM Stock Earnings: Immunome Misses EPS, Misses Revenue for Q2 2024
August 12, 2024
IMNM stock results show that Immunome missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities
July 25, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Appoints Phil Tsai as Chief Technical Officer
June 27, 2024
From
Immunome, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.